Variable name;level;Overall;Bondy;Clamart;Others;Port Royal;p;test
;n;262;118;80;6;55;;
Age;[0 -40);258 (98.5);116 (98.3);78 (97.5);6 (100.0);55 (100.0);0.693;
;40+;4 (1.5);2 (1.7);2 (2.5);0 (0.0);0 (0.0);;
Age (mean);;32.7 (3.7);32.8 (3.7);32.8 (3.9);31.0 (3.7);32.7 (3.7);0.736;
Number of children;0;177 (67.6);82 (69.5);47 (58.8);5 (83.3);42 (76.4);0.281;
;1;53 (20.2);25 (21.2);19 (23.8);1 (16.7);7 (12.7);;
;More than 1;32 (12.2);11 (9.3);14 (17.5);0 (0.0);6 (10.9);;
BMI;<18.5;16 (6.3);9 (7.7);0 (0.0);0 (0.0);7 (13.0);0.057;
;25-29.9;46 (18.0);19 (16.2);20 (26.7);0 (0.0);7 (13.0);;
;>=30;12 (4.7);5 (4.3);3 (4.0);1 (16.7);3 (5.6);;
;18.5-24.9;181 (71.0);84 (71.8);52 (69.3);5 (83.3);37 (68.5);;
BMI (mean);;22.0 [20.3, 24.5];21.9 [19.9, 24.0];23.0 [20.7, 25.3];20.9 [19.8, 22.4];21.4 [20.2, 23.4];0.052;nonnorm
Treatment center;Curie Paris;168 (64.1);93 (78.8);24 (30.0);1 (16.7);49 (89.1);NaN;
;Curie St Cloud;94 (35.9);25 (21.2);56 (70.0);5 (83.3);6 (10.9);;
;Others;0 (0.0);0 (0.0);0 (0.0);0 (0.0);0 (0.0);;
Genetic Analysis;No;55 (21.0);24 (20.3);21 (26.2);0 (0.0);10 (18.2);0.364;
;Yes;207 (79.0);94 (79.7);59 (73.8);6 (100.0);45 (81.8);;
Hereditary predisposition;No;159 (77.6);64 (69.6);52 (88.1);4 (66.7);36 (80.0);0.054;
;Yes;46 (22.4);28 (30.4);7 (11.9);2 (33.3);9 (20.0);;
Inflammatory BC;No;260 (99.2);116 (98.3);80 (100.0);6 (100.0);55 (100.0);0.492;
;Yes;2 (0.8);2 (1.7);0 (0.0);0 (0.0);0 (0.0);;
Clinical Tumor size (mm);;32.0 (20.2);31.9 (20.9);36.6 (22.5);32.8 (24.0);25.3 (11.9);0.017;
Clinical N stage (TNM);N0;165 (63.2);73 (61.9);47 (59.5);5 (83.3);37 (67.3);0.579;
;N1-N2-N3;96 (36.8);45 (38.1);32 (40.5);1 (16.7);18 (32.7);;
SBR grade;Grade I-II;107 (41.0);45 (38.5);39 (48.8);2 (33.3);21 (38.2);0.459;
;Grade III;154 (59.0);72 (61.5);41 (51.2);4 (66.7);34 (61.8);;
Histological type;NST;249 (95.0);113 (95.8);77 (96.2);6 (100.0);51 (92.7);0.938;
;Lobular;6 (2.3);2 (1.7);2 (2.5);0 (0.0);2 (3.6);;
;Others;7 (2.7);3 (2.5);1 (1.2);0 (0.0);2 (3.6);;
Neoajuvant chemotherapy;No;118 (45.0);48 (40.7);30 (37.5);4 (66.7);35 (63.6);0.009;
;Yes;144 (55.0);70 (59.3);50 (62.5);2 (33.3);20 (36.4);;
Chemotherapy setting;NAC;144 (55.0);70 (59.3);50 (62.5);2 (33.3);20 (36.4);NaN;
;Adjuvant;118 (45.0);48 (40.7);30 (37.5);4 (66.7);35 (63.6);;
;NAC and adjuvant;0 (0.0);0 (0.0);0 (0.0);0 (0.0);0 (0.0);;
;Chemotherapy without surgery;0 (0.0);0 (0.0);0 (0.0);0 (0.0);0 (0.0);;
;No;0 (0.0);0 (0.0);0 (0.0);0 (0.0);0 (0.0);;
Fertility preservation discussion;No;3 (1.1);0 (0.0);3 (3.8);0 (0.0);0 (0.0);0.079;
;Yes;259 (98.9);118 (100.0);77 (96.2);6 (100.0);55 (100.0);;
